This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
TFX Stock to Gain From Launch of New Vascular Access Devices in Canada
by Zacks Equity Research
Teleflex launches the next-generation Arrow VPS Rhythm DLX Device and NaviCurve Stylet in Canada.
West Pharmaceutical Stock Gains on Q3 Earnings Beat & Raised Guidance
by Zacks Equity Research
WST's third-quarter results reflect a recovery in the Proprietary Products segment following elevated customer destocking, hurting sales in the second quarter.
BSX Q3 Earnings Top, Stock Down in Premarket as Operating Margin Falls
by Zacks Equity Research
Boston Scientific registers year-over-year improvement in sales, indicating solid market share gains in legacy businesses despite macroeconomic odds.
Intuitive Surgical Q3 Earnings Beat, Procedures Robust
by Zacks Equity Research
ISRG's third-quarter results reflect a healthy demand for procedures. Higher pricing boosts procedure sales. An improvement in margins buoys well.
Globus Medical Expands Orthopedic Trauma Portfolio With New Launches
by Zacks Equity Research
GMED launches ANTHEM II Distal Radius Volar Plates, AUTOBAHN Trochanteric Nail PRO Instruments and CAPTIVATE SOLA Headless Screws.
GMED or SONVY: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
GMED vs. SONVY: Which Stock Is the Better Value Option?
Why Is Globus Medical (GMED) Down 0.2% Since Last Earnings Report?
by Zacks Equity Research
Globus Medical (GMED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Is It Apt to Hold Globus Medical Stock in Your Portfolio Now?
by Zacks Equity Research
GMED's robust prospects in the musculoskeletal field and the synergies from the NuVasive merger bode well. Yet, macroeconomic issues can affect performance.
Globus Medical's (GMED) Lateral Interbody Portfolio Gets New Launch
by Zacks Equity Research
Globus Medical's (GMED) lateral interbody portfolio gets its first commercial product launch with ADIRA XLIF Plate System.
Zimmer Biomet's (ZBH) Latest Deal to Expand Its Hip Portfolio
by Zacks Equity Research
Zimmer Biomet (ZBH) announces the acquisition of OrthoGrid to expand its hip portfolio with an AI-driven surgical guidance system.
Here's Why Globus Medical (GMED) is a Strong Momentum Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why Globus Medical (GMED) is a Strong Growth Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Globus Medical (GMED) Q2 Earnings Top Estimates, '24 View Up
by Zacks Equity Research
Globus Medical (GMED) delivers massive sales and earnings growth in the second quarter of 2024. However, margins contract.
Globus Medical (GMED) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
The headline numbers for Globus Medical (GMED) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Globus Medical (GMED) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Globus Medical (GMED) delivered earnings and revenue surprises of 10.29% and 2.39%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Globus Medical (GMED) Q2 Earnings Preview: What You Should Know Beyond the Headline Estimates
by Zacks Equity Research
Get a deeper insight into the potential performance of Globus Medical (GMED) for the quarter ended June 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
3 Reasons Why You Should Hold HealthEquity (HQY) Stock Now
by Zacks Equity Research
HealthEquity's (HQY) sustained strength in HSAs raises optimism about the stock.
West Pharmaceutical (WST) Misses on Q2 Earnings, Lowers '24 View
by Zacks Equity Research
West Pharmaceutical's (WST) second-quarter results reflect a declining demand for products across its segments amid elevated customer destocking.
Boston Scientific (BSX) Q2 Earnings Beat, Organic Sales Rise
by Zacks Equity Research
Boston Scientific (BSX) registers a strong year-over-year improvement in sales, indicating solid market share gains in legacy businesses across all geographic regions.
Veeva Systems' (VEEV) Vault EDC to Boost Vita Global's Workflow
by Zacks Equity Research
Veeva Systems' (VEEV) Vault EDC is likely to aid the CRO in delivering a better experience to patients, research sites and sponsors.
Thermo Fisher (TMO) Beats on Q2 Earnings, Raises 2024 EPS View
by Zacks Equity Research
The year-over-year decline in Thermo Fisher's (TMO) Life Science Solutions and Laboratory Products and Biopharma Services revenues disappoints. However, margins expand in the second quarter.
Quest Diagnostics' (DGX) Haystack Oncology Forges New MRD Deal
by Zacks Equity Research
Quest Diagnostics' (DGX) subsidiary, Haystack Oncology, partners on the use of its MRD technology.
Inspire Medical's (INSP) Inspire Therapy Gets CE Mark Approval
by Zacks Equity Research
Inspire Medical's (INSP) receipt of the latest CE mark certification will likely enable it to continue to deliver Inspire products globally.
Globus Medical (GMED) Global Sales, Innovation Aid Growth
by Zacks Equity Research
In line with the company's business strategy to focus on its integrated product development, Globus Medical (GMED) is consistently making efforts in research and development.
Intuitive Surgical (ISRG) Q2 Earnings Beat, Procedures Robust
by Zacks Equity Research
Intuitive Surgical's (ISRG) second-quarter results reflect a healthy demand for procedures. Higher pricing boosts procedure sales. An improvement in margins buoys well.